Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > International Molecular Screening Program for… >

International Molecular Screening Program for Metastatic Breast Cancer AURORA at IMPAKT

Published: May 7, 2014.
Released by Breast International Group (BIG)-aisbl  

While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored. Moreover, despite the fact that the overall breast cancer death rate has dropped steadily over the last decade and significant improvements in survival have been made, metastatic breast cancer represents the leading cause of death among patients with the disease.

In this context the Breast International Group (BIG) recently launched AURORA, which will use molecular screening to improve our understanding of metastatic breast cancer and its response or lack of response to available drug therapies. In total 1300 women and men from about 60 hospitals in 15 European countries are expected to take part in the programme. Over time, BIG hopes to expand the programme well beyond Europe to involve several 1000 more patients.

Dr Martine Piccart-Gebhart, Chair of BIG and Director of the Medicine Department of the Institut Jules Bordet, strongly believes in this research programme and says: "It is almost unethical that we continue to treat women with metastatic breast cancer when we have so little knowledge of their disease. We now have powerful technologies for investigating the molecular landscape of tumours, and we have an obligation to women to establish AURORA as a large translational research effort that can hopefully lead to more effective treatments in the future".

Within AURORA, metastatic and primary breast cancer tissue specimens will be collected and screened with a panel of more than 400 cancer-related genes for the first time on a large scale. Plasma and blood samples will also be collected, and any samples not analysed immediately will be stored in an independent bio-repository to enable future research. An innovative bioinformatics platform has been developed to support the collection of AURORA data. These data are being collected in a way that will allow sharing and collaborating in the context of other initiatives started by researchers in North America.

AURORA will enable scientists to understand both why breast cancer metastasises and why some patients respond poorly to standard treatment, while others respond very well. Whenever possible, patients participating in AURORA will be offered to participate in a clinical trial testing new and promising drugs that target the specific genetic characteristics of their tumours. The ultimate hope is that AURORA will benefit patients by leading us to both better treatments and to finding cures for the women and men affected by this disease.

The above story is based on materials provided by Breast International Group (BIG)-aisbl.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish

comments powered by Disqus

Related »

UK Researchers Present Findings from Kentucky Breast Cancer Patients with Disease Relapse
The University of Kentucky Markey Cancer Center breast oncologist Dr. Suleiman Massarweh and his research team presented findings from …
Drug to Reverse Breast Cancer Spread in Development
Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells. …
An Important Discovery in Breast Cancer by IRCM Researchers
Montréal, April 15, 2013 – A team of researchers at the IRCM, led by Dr. Jean-François Côté, made an …
What Should Be the Goal of Treatment in Metastatic Breast Cancer?
Barcelona, Spain: Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should …
CWRU School of Medicine Researchers Discover New Molecule Linked to Late-stage Breast Cancer
CLEVELAND -- Researchers at Case Western Reserve University School of Medicine have identified a molecule linked to more aggressive …
Potential New Therapeutic Target for a Subset of Aggressive Breast Cancers
The main cause of death in women with breast cancer is spread of the original tumor to distant sites, …
Research Explores How Breast Cancer Spreads And New Ways to Treat It
ORLANDO, Fla. — August 3, 2011 — Research into new methods to prevent and slow metastatic breast cancer will …
New Drug Combination Delayed Disease Progression for Subgroup of Women with Metastatic Breast Cancer
SAN ANTONIO — Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed …

Breast Cancer Vaccine Shows Promise in Small Clinical Trial
New Drug Combination for Advanced Breast Cancer Delays Disease Progression
New Haven, Conn. - A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast …
Worse Outcomes for Older Breast Cancer Patients with Other Health Problems
Older breast cancer patients with certain other health problems have higher mortality rates than patients without these problems according …
TRPM7 Protein Key to Breast Cancer Metastasis in Animal Models
PHILADELPHIA — The protein transient receptor potential melastatin-like 7 (TRPM7) is a critical determinant of breast cancer cell metastasis, …
Cancer Vaccine Combination Therapy Shows Survival Benefit in Breast Cancer
(SACRAMENTO, Calif.) — A vaccine that targets cancer cells in combination with the drug letrozole, a standard hormonal therapy …
New Combination Therapy Fails to Delay Progression of Advanced Breast Cancer
SAN ANTONIO — Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for …
More » 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile